Geode Capital Management’s Alterity Therapeutics ATHE Stock Holding History

Geode Capital Management’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,213	Closed	-$5K	–	4899
2022 Q3	$5K	Hold	1,213	–	–	﹤0.01%	5011
2022 Q2	$7K	Hold	1,213	–	–	﹤0.01%	4994
2022 Q1	$9K	Hold	1,213	–	–	﹤0.01%	4963
2021 Q4	$8K	Hold	1,213	–	–	﹤0.01%	4969
2021 Q3	$15K	Hold	1,213	–	–	﹤0.01%	4841
2021 Q2	$15K	Hold	1,213	–	–	﹤0.01%	4713
2021 Q1	$17K	Hold	1,213	–	–	﹤0.01%	4445
2020 Q4	$16K	Hold	1,213	–	–	﹤0.01%	4259
2020 Q3	$24K	Hold	1,213	–	–	﹤0.01%	4109
2020 Q2	$14K	Hold	1,213	–	–	﹤0.01%	4083
2020 Q1	$7K	Hold	1,213	–	–	﹤0.01%	4095
2019 Q4	$9K	Hold	1,213	–	–	﹤0.01%	4194
2019 Q3	$14K	Hold	1,213	–	–	﹤0.01%	4170
2019 Q2	$16K	Buy	+1,213	New	+$19.4K	﹤0.01%	4170
2015 Q3	–	Sell	-312	Closed	-$21K	–	4126
2015 Q2	$21K	Buy	+312	New	+$23.4K	﹤0.01%	3933

Other funds holding ATHE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

PCA

Providence Capital Advisors Charlotte, North Carolina $613M AUM 17.83% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

SWM

Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

Geode Capital Management's ATHE Position: Q4 2022 in Review

Geode Capital Management sold out of Alterity Therapeutics (ATHE) in Q4 2022, closing a stake of 1,213 shares — an estimated $5K sold.

Geode Capital Management first reported a position in ATHE in Q2 2015 and held it in 15 quarters. The position peaked at $24K in Q3 2020. 12 funds tracked by Wall St. Rank hold ATHE as of Q4 2022.

Geode Capital Management reported no remaining Alterity Therapeutics position as of Q4 2022 after selling out during the quarter.
Geode Capital Management sold 1,213 Alterity Therapeutics shares in Q4 2022, an estimated $5K.
Geode Capital Management first reported a position in Alterity Therapeutics in Q2 2015 and held it in 15 quarters.
Geode Capital Management's Alterity Therapeutics position peaked at $24K in Q3 2020.
12 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q4 2022.

Based on Geode Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.